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Introduction
Point-of-care testing (POCT), or near-patient testing, is 
the fastest growing segment of diagnostic laboratories 
in the developed world. Laboratories have become 
increasingly involved in supporting testing away from the 
conventional laboratory setting, to improve the quality and 
cost of healthcare delivery. POCT has been validated within 
hospitals and general practice to assist with urgent patient 
management, by providing rapid laboratory test results.1-5 
Measurement of haemoglobin (Hb) alone is a valuable 
screening test for anaemia, and has an important role in 
POCT.1 Anaemia is common in pregnant women, infants 
and preschool children.6 Anaemia is suspected on the 
basis of clinical signs and symptoms. If the Hb is below 
the lower limit of normal for age, gender and altitude, 
additional laboratory parameters, including red cell indices, 
a reticulocyte count and review of the peripheral smear, will 
assist further assessment of the anaemia. 
The introduction of POCT for Hb measurement offers distinct 
advantages.7-11 These include improved turnaround time, a 
small sample volume required for testing, and long-term 
cost savings.5 The volume required for analysis is very small 
(10 µl), making this device particularly suitable for paediatric 
and neonatal Hb measurements, as blood sampling in this 
age group is often technically difficult and distressing. 
More recently, POCT devices that require capillary blood 
samples have become available for measuring Hb with 
enhanced speed, simplicity and analytical performance.3-5 
The most popular haemoglobinometer is the HemoCue® 
(Aktiebolaget Leo Diagnostics, Helsingborg, Sweden), 
which is a small bench-top device, suitable for use in 
doctors’ offices. It measures Hb by converting haemoglobin 
into haemoglobinazide.12 Whole blood collected by capillary 
or venous sampling (10 µl) is placed into the cuvette 
(containing dried reagents) in the cuvette holder. Light 
absorbance is measured at two wavelengths, namely 565 
and 880 nm (to compensate for any turbidity in the sample). 
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The instrument then calculates the Hb in the sample, and 
displays the results within 45 seconds.
Other locally available small hand-held devices include 
the STAT-Site® M Hgb (Stanbio Laboratories,Texas, USA) 
and the Spencer® haemoglobinometer (Buffalo Medical 
Specialities, Buffalo, New York, USA). In comparison to 
these devices,13,14 the HemoCue® shows the highest level 
of agreement with automated haematology analysers, 
with a reported correlation of 99% when used by trained 
operators.15 It complies with the International Committee 
on Standardization in Haematology’s standards for 
haemoglobin measurement (ICSH, 1996).16
An evaluation of the HemoCue® device was performed to 
compare its analytical performance with regard to accuracy, 
precision and linearity in the measurement of Hb with that 
of the Coulter® LH 750 automated haematology analyser 
(Beckman Coulter, Miami, Florida, USA). 
Method
Ethical approval
Ethical approval for the study was obtained from the 
University of Witwatersrand human research ethics 
committee. This validation was performed in accordance 
with the ICSH 1993, and the method comparison from 
the Clinical and Laboratory Standards Institute (CLSI EP9, 
USA).17
Study period
The validation was performed at the National Health 
Laboratory Service at the Charlotte Maxeke Johannesburg 
Academic Hospital over a two-week period. 
Patient samples
Blood samples used were those left after routine diagnosis 
carried out on adult and paediatric patients at the main 
hospital laboratory. Ethylenediaminetetracetic acid samples 
obtained by venepuncture, heel prick, or from arterial lines 
with volumes more than 20 µl were used. 
Evaluation procedure
For the method comparison study, a prospective, 
side-by-side comparative study of the HemoCue® 
haemoglobinometer against the Coulter® LH 750 automated 
haematology analyser was performed. Hb measurement 
was taken in duplicate on 100 adult and paediatric patient 
samples that were referred for routine testing. The samples 
were analysed sequentially by the same technologist on the 
HemoCue® and Coulter® LH 750 haematology analysers 
using the respective instruments’ standard operating 
procedures. There was no aliquoting or sample splitting. 
Within-run precision evaluation was performed with the 
normal and abnormal HemoTrol reference control analysed 
20 times.
Linearity was assessed by diluting known patient samples 
with high Hb levels, 1:2; 1:4; 1:8; and 1:16, with isoton or 
normal saline. The linearity findings were used to determine 
the analysers’ reportable range and lower limit of detection.
Statistical analysis
Results were collated on an Excel spreadsheet, tabulated, 
and graphically summarised using standard statistical 
methods. Agreement between results obtained on the 
different analysers was evaluated using standard scatter 
and difference plots.  
Results
One hundred samples were identified and qualified for 
analysis by both instruments. The mean Hb value of the 
HemoCue® (11.3 g/dl; range 4.6-16.7), was comparable 
to that of the Coulter® LH 750 (11.3 g/dl; range 4.7-17.2). 
The Bland-Altman difference plot revealed good correlation. 
Bias between the two methods was small (0.76%). The limit 
of agreement between the two methods is demonstrated 
in the difference plot, according to Bland-Altman (see 
Figure 1). The intra-assay coefficients of variation (CV) were 
within allowable limits of performance in the normal and 
pathological range (1.75% and 1.51% respectively). The 
results of the intra-assay precision for the normal reference 
control are shown in Figure 2. Hb measurement was linear 
in the range of 4.8-20 g/dl (see Figure 3). 
Seven data points are outside the 95% limits of agreement. 
However, the bias is small (0.76%). 
At the allowable precision limit of 1.4, there is a linear 
relationship between the observations and mean difference 
as a function of imprecision.
Hb measurement is linear, in the range of 4.8-20 g/dl.
Discussion	
In this prospective study, we demonstrated the clinical utility 
of the HemoCue® point-of-care device for the diagnosis of 
anaemia. The HemoCue® is a portable haemoglobinometer 
that was introduced into the clinical setting over 20 years 
ago for Hb measurement. 
This study demonstrated acceptable agreement between 
the HemoCue® and laboratory measurement with the 
Coulter® LH 750 automated haematology analyser. Ninety-
five per cent of the values had a clinically significant 
difference of < 1 g/dl, making this an acceptable method. 
The HemoCue® was accurate over a wide Hb range 
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(4.8-20 g/dl) for the diagnosis and monitoring of anaemia 
and polycythemia. When used under standard laboratory 
conditions, the HemoCue® is an accurate method for 
determining Hb. In addition, studies performed by non-
technical staff in a clinic or general practice, show a similar 
level of accuracy and precision.18 Several research groups 
have demonstrated the advantages of having a simple and 
reliable POCT for the diagnosis of anaemia without having 
to perform venepuncture.7-11 The introduction of POCT has 
improved patient care and accessibility in these settings. 
In South Africa, the highest burden of anaemia occurs in 
the first year of life.6 Although this disorder is common, it 
frequently remains undetected and untreated. This study 
included a large number of paired neonatal and paediatric 
samples (n = 50). The introduction of the Hb POCT in 
paediatric patients would have a number of advantages. 
The HemoCue® would allow for rapid Hb determination, 
using small sample volumes (10 µl). The most common 
error reported when measuring Hb in the laboratory is an 
insufficient sample, as most analysers require a minimum 
sample volume of 500 µl. 
In addition to being a simple device to operate, the 
HemoCue® offers potential cost savings. Initially, there 
would be increased expenses as a result of the cost per 
unit, which includes analyser, cuvettes and reagents, which 
would need to be supplied and distributed. The initial 
introduction might also result in increased over-servicing, 
and this would need to be closely monitored. However, 
the literature has demonstrated the potential long-term 
cost-saving benefits of implementing the HemoCue® in 
a hospital setting.5,19-20 These include the elimination of 
the preanalytical and many of the analytical steps in the 
diagnostic process, some of which include skilled staff, 
bar codes, equipment and reagents. Specific to our current 
local setting, where the power supply is inconsistent, the 
HemoCue®, which is a battery-operated device, will prove 
to be highly beneficial.
It is imperative that implementation of POCT is accompanied 
by guidelines that reflect current best practice.20 These 
guidelines should be strictly adhered to by all staff who 
operate the device. A quality system should be defined, 
where results are validated by satisfactory performance 
in internal and external quality-assessment schemes. For 
example, an internal quality control (IQC) test should be 
performed at the start of the day before any patient analysis 
is performed. Further IQC should also be performed with 
every new batch of cuvettes to ensure there has been no 
deterioration during storage. Moreover, abnormal results 
must be appropriately flagged. A system should be 
established for appropriate referral to the supporting local 
Figure 1: Bland-Altman difference plot for Hb measurement with the 
HemoCue® and Coulter® LH 750
Figure 2: Precision plot of normal Hb measurements 
Figure 3: Linearity plot of HemoCue® Hb measurements 
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reference laboratory for out-of-range results for further 
investigation. In specific settings, full blood count analysis 
and repeat samples may be required. Close cooperation 
with the local laboratory service is also required to ensure 
adequate training and education of the staff who will be 
performing the tests. 
Conclusion
In this cohort, the HemoCue® provided accurate and reliable 
Hb measurements for a wide range of Hb for the diagnosis 
of anaemia. The advantages of HemoCue® over standard 
haematology analysers are the small volume required, and 
rapid turnaround times. Although this does not replace full 
blood count testing, it is a useful adjunct to monitoring 
anaemia in all age groups.
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